Home/Filings/4/0001415889-24-029694
4//SEC Filing

Javitt Jonathan C 4

Accession 0001415889-24-029694

CIK 0001719406other

Filed

Dec 17, 7:00 PM ET

Accepted

Dec 18, 8:27 AM ET

Size

7.8 KB

Accession

0001415889-24-029694

Insider Transaction Report

Form 4
Period: 2024-12-17
Javitt Jonathan C
DirectorChairman and Chief Scientist10% Owner
Transactions
  • Purchase

    Common Stock

    2024-12-17$1.17/sh+40,000$46,80084,634 total
Holdings
  • Common Stock

    (indirect: By the Jonathan Javitt Donor Advised Fund)
    30,000
  • Common Stock

    (indirect: By Trust)
    1,260,000
  • Common Stock

    (indirect: By Trust)
    142,200
Footnotes (3)
  • [F1]Held by the Jonathan Javitt Living Trust of which the reporting person is the trustee.
  • [F2]Held by the Javitt 2012 Irrevocable Dynasty Trust of which the reporting person is the grantor of such trust. The reporting person is not a trustee or beneficiary of the Trust, and no beneficiary of the Trust resides in the reporting person's household. The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
  • [F3]Held by the Jonathan Javitt Donor Advised Fund of which the reporting person is the primary advisor of such fund.

Issuer

NRX Pharmaceuticals, Inc.

CIK 0001719406

Entity typeother

Related Parties

1
  • filerCIK 0001303782

Filing Metadata

Form type
4
Filed
Dec 17, 7:00 PM ET
Accepted
Dec 18, 8:27 AM ET
Size
7.8 KB